228 related articles for article (PubMed ID: 16077066)
21. Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 - 2010).
Ban HS; Uto Y; Nakamura H
Expert Opin Ther Pat; 2011 Feb; 21(2):131-46. PubMed ID: 21210751
[TBL] [Abstract][Full Text] [Related]
22. Targeting hypoxia cell signaling for cancer therapy.
Melillo G
Cancer Metastasis Rev; 2007 Jun; 26(2):341-52. PubMed ID: 17415529
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.
Otrock ZK; Hatoum HA; Awada AH; Ishak RS; Shamseddine AI
Crit Rev Oncol Hematol; 2009 May; 70(2):93-102. PubMed ID: 19186072
[TBL] [Abstract][Full Text] [Related]
24. The era of cancer discovery.
Cantley LC; Baselga J
Cancer Discov; 2011 Jun; 1(1):1. PubMed ID: 22586302
[No Abstract] [Full Text] [Related]
25. Researchers may use cancer cell lines to identify target populations prior to clinical trials.
Tuma RS
J Natl Cancer Inst; 2006 Jun; 98(12):810-1. PubMed ID: 16788154
[No Abstract] [Full Text] [Related]
26. Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo.
Jordan BF; Black K; Robey IF; Runquist M; Powis G; Gillies RJ
NMR Biomed; 2005 Nov; 18(7):430-9. PubMed ID: 16206237
[TBL] [Abstract][Full Text] [Related]
27. Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development.
Martínez-Sánchez G; Giuliani A
J Exp Clin Cancer Res; 2007 Mar; 26(1):39-50. PubMed ID: 17550131
[TBL] [Abstract][Full Text] [Related]
28. MS-209 Schering.
Robert J
Curr Opin Investig Drugs; 2004 Dec; 5(12):1340-7. PubMed ID: 15648956
[TBL] [Abstract][Full Text] [Related]
29. The hypoxic inducible stress response as a target for cancer drug discovery.
Welsh SJ; Koh MY; Powis G
Semin Oncol; 2006 Aug; 33(4):486-97. PubMed ID: 16890803
[TBL] [Abstract][Full Text] [Related]
30. Inducing indigestion: companies embrace autophagy inhibitors.
Garber K
J Natl Cancer Inst; 2011 May; 103(9):708-10. PubMed ID: 21515831
[No Abstract] [Full Text] [Related]
31. Inhibiting hypoxia-inducible factor 1 for cancer therapy.
Melillo G
Mol Cancer Res; 2006 Sep; 4(9):601-5. PubMed ID: 16940159
[TBL] [Abstract][Full Text] [Related]
32. The search for novel drug leads for predominately antitumor therapies by utilizing mother nature's pharmacophoric libraries.
Kingston DG; Newman DJ
Curr Opin Drug Discov Devel; 2005 Mar; 8(2):207-27. PubMed ID: 15782545
[TBL] [Abstract][Full Text] [Related]
33. An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.
Gradishar WJ
Invest New Drugs; 1997; 15(1):49-59. PubMed ID: 9195289
[TBL] [Abstract][Full Text] [Related]
34. Present research trends in cancer chemotherapy.
Eckhardt S
Acta Med Hung; 1994; 50(3-4):133-40. PubMed ID: 8587825
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia in tumors: molecular targets for anti-cancer therapeutics.
Williams KJ; Cowen RL; Brown LM; Chinje EC; Jaffar M; Stratford IJ
Adv Enzyme Regul; 2004; 44():93-108. PubMed ID: 15581485
[No Abstract] [Full Text] [Related]
36. AN-9 (Titan).
Hobdy E; Murren J
Curr Opin Investig Drugs; 2004 Jun; 5(6):628-34. PubMed ID: 15242252
[TBL] [Abstract][Full Text] [Related]
37. Cancer drugs in pipeline span wide spectrum.
McCann J
J Natl Cancer Inst; 2001 Mar; 93(6):424-6. PubMed ID: 11259465
[No Abstract] [Full Text] [Related]
38. Slow start to phase 0 as researchers debate value.
Twombly R
J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150
[No Abstract] [Full Text] [Related]
39. HIF-1 blockade inhibits gastric cancer growth in mice.
Cancer Biol Ther; 2004 Jul; 3(7):587. PubMed ID: 15751162
[No Abstract] [Full Text] [Related]
40. The role of the National Cancer Institute in drug development.
Doroshow J
Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
